GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?

Affiliations

¹ Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany; Division of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. Electronic address: Elric.Zweck@ddz.uni-duesseldorf.de.
² Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany; Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.

Comment

Elric Zweck et al. Lancet Diabetes Endocrinol. 2019 Feb.

. 2019 Feb;7(2):89-90.

doi: 10.1016/S2213-8587(18)30351-6.

¹ Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany; Division of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. Electronic address: Elric.Zweck@ddz.uni-duesseldorf.de.
² Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany; Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.

No abstract available

Comment on

GLP-1 receptor agonists: differentiation within the class.
Taylor SI. Taylor SI. Lancet Diabetes Endocrinol. 2018 Feb;6(2):83-85. doi: 10.1016/S2213-8587(17)30413-8. Epub 2017 Dec 6. Lancet Diabetes Endocrinol. 2018. PMID: 29221658 Free PMC article. No abstract available.